Lonza Group sets long term strategy focus, shares reflect mixed sector performance

Lonza Group is back on investors’ radar with its long term contract development and manufacturing strategy in focus, as sector peers like Lonza and Catalent continue to reshape the global biotech services landscape.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-22, 20:09.

Lonza Group (CH0013841017) remains a core health care name on the SIX Swiss Exchange as investors assess its long term contract development and manufacturing services strategy relative to global peers. The stock trades in a sector that includes players such as Catalent and Thermo Fisher Scientific, both of which are also key suppliers to the biopharmaceutical industry.

Lonza in the life sciences services landscape

Lonza Group positions itself as a leading global partner for the pharmaceutical and biotech industries, offering services from early development through commercial manufacturing of drug substances and finished dosage forms. According to the company’s own materials, its network of sites spans Europe, North America and Asia, giving it geographic diversification across major pharma clusters.

Peer companies such as Catalent and Thermo Fisher’s pharma services division pursue similar asset heavy, long term contract models in biologics, cell and gene therapies and small molecules, making the competitive field dense but structurally growing as biologic drugs take more share of global sales.

Long term contracts and capacity as strategic levers

Lonza’s strategy centers on high value long term contracts with large pharma and biotech customers, underpinned by significant capital expenditure to expand and modernize manufacturing capacity. This includes investments in biologics plants, cell and gene therapy facilities and specialized small molecule sites that typically require multi year lead times and careful utilization planning.

Such capacity expansion programs are common across the sector, as shown by comparable initiatives at Catalent and Thermo Fisher, and they are intended to secure future revenue visibility while positioning suppliers for structurally rising demand for complex biologics and advanced therapies.

How Lonza generates its revenue

Lonza generates most of its revenue by developing and manufacturing active pharmaceutical ingredients and finished dosage forms for third party customers, primarily under long term contracts. This includes biologics such as monoclonal antibodies and antibody drug conjugates, as well as cell and gene therapy products and small molecule APIs.

Where the shares trade today

The Lonza Group shares (CH0013841017) trade on the SIX Swiss Exchange, with prices quoted in Swiss francs alongside other large Swiss health care names.

Lonza Group in brief

• Company: Lonza Group AG
• ISIN: CH0013841017
• WKN: 928619
• Ticker: LONN
• Trading venue: SIX Swiss Exchange
• Price (as of 2026-06-22, 18:00): n.a. CHF
• Market cap: n.a. CHF (as of 2026-06-22)
• Sector / industry: Health Care - Life Sciences Tools & Services
• Index membership: SMI / SPI
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.